OBJECTIVES:  To trace the epidemiological profile and financial impact to cover the anti angiogenic treatment for neovascular age-related macular degeneration and macular edema secondary to central retinal vein occlusion to a health care system of public employees located in northeastern Brazil between July 1, 2015 and December 31, 2015. METHODS: A retrospective cohort study. They were evaluated in 954 intravitreal applications authorized in this period using ranibizumab or aflibercept for neovascular age-related macular degeneration and macular edema secondary to occlusion of the central retinal vein. Age, sex, ICD and costs were compared in both pathologies coverage. Data were collected in the electronic system of this health system and analyzed using Microsoft Excel 2007 spreadsheets and statistical calculations for SPSS Statistics 17.0. RESULTS:   Based on the literature, was adopted protocol developed by this health system with coverage to age 60 years in cases of macular degeneration related to age. It analyzed authorized applications 954, and 836 for neovascular age-related macular degeneration and 118 for macular edema secondary to central retinal vein occlusion. In most cases it was found as the cause macular degeneration. The cost for neovascular age-related macular degeneration in the same period was USD 449,735 while for macular edema secondary to central retinal vein occlusion was USD 59,377. The total cost of both directions in the same period was approximately USD 509,112. CONCLUSIONS:  Although all treatments available are limited, they cause a favorable impact on quality of life which justifies their use, although in 2015 the definition of the drug manufacturer's price in CMED appears the factory value of the drug ranibizumab USD928 and aflibercept USD 910, the value traded to cover for anti angiogenic treatment application was USD 588 contemplating medical fee, rate, material and medicine.